Abeona Therapeutics Reports Material Agreement & New Financial Obligation

TL;DR

**Abeona Therapeutics just reported a new material agreement and financial obligation, but the filing is light on details.**

AI Summary

On January 8, 2024, Abeona Therapeutics Inc. filed an 8-K to report an "Entry into a Material Definitive Agreement" and the "Creation of a Direct Financial Obligation." While the filing indicates these significant events, it does not provide specific details about the nature of the agreement or the financial obligation. This lack of detail means investors are currently in the dark about potential impacts on the company's financial health or strategic direction, which could introduce uncertainty for current or prospective shareholders.

Why It Matters

This filing signals significant corporate actions, but without details, investors cannot assess the potential positive or negative financial implications for Abeona Therapeutics Inc.

Risk Assessment

Risk Level: medium — The filing indicates significant financial and contractual changes without providing specifics, creating uncertainty and potential risk for investors.

Analyst Insight

A smart investor would await further detailed disclosures from Abeona Therapeutics Inc. regarding the material agreement and financial obligation before making any investment decisions, as the current filing lacks critical information to assess impact.

Key Players & Entities

• ABEONA THERAPEUTICS INC. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of the earliest event reported and filing date

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value ABEO The Nasdaq Capital M
• $50 m — in an aggregate principal amount up to $50 million, with (i) a committed tranche of
• $20 million — illion, with (i) a committed tranche of $20 million advanced on the Closing Date (" Tranche
• $10 million — 1 "), (ii) a committed tranche of up to $10 million which may be advanced upon the request
• $90 million — ew Voucher and (ii) the Company raising $90 million of cumulative equity and/or non-dilutiv
• $5 million — ng the Company to maintain at all times $5 million in unrestricted cash. The Loan Agreemen
• $3 million — nue also has the right to convert up to $3 million of the outstanding principal of the Loa
• $1 million — Company in an aggregate amount of up to $1 million on the same terms, conditions and prici
• $480,000 — ntholders ") warrants to purchase up to $480,000 and $1,920,000 worth of shares, respect
• $1,920,000 — warrants to purchase up to $480,000 and $1,920,000 worth of shares, respectively, of Compa
• $4.75 — ce per share equal to the lesser of (i) $4.75 and (ii) the price per share of the Com

Filing Documents

• form8-k.htm (8-K) — 59KB
• ex4-1.htm (EX-4.1) — 122KB
• ex4-2.htm (EX-4.2) — 121KB
• ex10-1.htm (EX-10.1) — 344KB
• ex10-2.htm (EX-10.2) — 289KB
• ex99-1.htm (EX-99.1) — 13KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• ex4-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-001660.txt ( ) — 1282KB
• abeo-20240108.xsd (EX-101.SCH) — 3KB
• abeo-20240108_lab.xml (EX-101.LAB) — 33KB
• abeo-20240108_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 8, 2024 ABEONA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-15771 83-0221517 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6555 Carnegie Ave , 4th Floor Cleveland , OH 44103 (Address of principal executive offices) (Zip Code) (646) 813-4701 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value ABEO The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01. Entry into a Material Definitive Agreement. Loan and Security Agreement On January 8, 2024 (the " Closing Date "), Abeona Therapeutics Inc., a Delaware corporation (" Abeona ") and its subsidiaries MacroChem Corporation, a Delaware corporation (" MacroChem ") and Abeona Therapeutics LLC, an Ohio corporation (" Abeona OH " and, together with Abeona and MacroChem, each individually, a " Company " and collectively, the " Companies ") entered into a Loan and Security Agreement (the " Agreement ") with Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership, as administrative agent and collateral agent (" Avenue " and the " Agent ") and Avenue Venture Opportunities Fund II, L.P. , a Delaware limited partnership (" Avenue 2 " and, together with Avenue, the " Lenders "). Also on January 8, 2024, the Companies entered into a Supplement to the Agreement (collectively with the Agreement, the " Loan Agreement ") with the Agent and the Lenders. The Loan Agreement provides for senior secured term loans (the " Loans ") in an aggregate principal amount up to $50 million, with (i) a committed tranche of $20 million advanced on the Closing Date (" Tranche 1 "), (ii) a committed tranche of up to $10 million which may be advanced upon the request of the Company between June 30, 2024 and September 30, 2024, subject to the Company obtaining FDA approval of pz-cel in recessive dystrophic epidermolysis bullosa, with the issuance of a Priority Review Voucher (" Tranche 2 "), and (iii) a discretionary tranche of up to $20 million which may be advanced between March 31, 2025 and March 31, 2026 (the " Discretionary Tranche ") provided at the discretion of the Lenders. The Loans are due and payable on July 1, 2027 (the " Maturity Date "). The proceeds of the Loans are to be used for general corporate purposes. The Loan principal is repayable in equal monthly installments beginning on April 8, 2025, with the possibility of deferring principal payments an additional nine to fifteen months contingent upon (i) the Company obtaining FDA approval of pz-cel in recessive dystrophic epidermolysis bullosa, with the issuance of a Priority Review Voucher and (ii) the Company raising $90 million of cumulative equity and/or non-dilutive capital subsequent to the Closing Date. The Loans bear interest at a rate per annum (subject to increase during an event of default) equal to the greater of (i) the prime rate, as published by the Wall Street Journal from time to time, plus 5.00% and (ii) 13.50%. The Company may, subject to certain parameters, voluntarily prepay the Loans, in whole, at any time. If prepayment occurs on or before the one-year anniversary of the Closing Date, the Company is required to pay a prepayment fee equal to 3.00% of the principal amount of the Loans prepaid; if prepayment occurs after the one-year anniversary of the Closing Date and on or before the two-year anniversary o

View Full Filing

View this 8-K filing on SEC EDGAR